Intimation of signing of letter of Intent.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Astal Laboratories has signed a Letter of Intent (LOI) with Switzerland-based Immuna Therapeutics GmbH to secure exclusive India rights for next-generation CAR-T cell therapies, including TriCAR-T platforms. The collaboration covers technology transfer, local manufacturing, clinical development, and commercialization in India. The company estimates this partnership could generate incremental revenue of approximately ₹300 crore once implemented, driven by rising demand for advanced oncology treatments. This move aligns with Astal's long-term strategy to enter high-value advanced therapies and cell and gene therapy platforms. However, the announcement is an LOI, meaning a binding agreement and execution are still pending.
If the collaboration materializes into a binding contract, the ₹300 crore revenue potential could be a major growth driver for Astal Labs, potentially transforming its business profile. Shareholders should view this as a positive long-term strategic development, though near-term stock impact may be limited since it is only a Letter of Intent and actual revenue realization depends on successful execution, regulatory clearances, and clinical milestones.